TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
Regeneron Pharmaceuticals of Tarrytown, N.Y., announced positive results from a second late-stage clinical trial showing that its drug Arcalyst, currently approved for a rare disease, can treat gout, ...
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa launches Kiniksa One Connect™ patient support program -- ...
TARRYTOWN, N.Y., July 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the ...
Since launch, more than 4,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis. Kiniksa also provided updates on its development pipeline, noting that data from the Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results